2.6(top 6%)
Impact Factor
2.9(top 6%)
extended IF
109(top 3%)
H-Index
2.9K
authors
5.6K
papers
128.2K
citations
5.3K
citing journals
32.7K
citing authors

Most Cited Articles of Lupus

TitleYearCitations
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines2003585
Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden2006554
Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus2000392
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies2011351
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies2000349
Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients2007306
Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity2004281
Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus2006279
Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study2001275
Mechanisms of action of mycophenolate mofetil2005274
Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture1999260
Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis2002256
Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)2008241
A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection1992238
Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases2009237
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity1995236
Cardiac involvement in systemic lupus erythematosus2005230
The innate immune system in SLE: type I interferons and dendritic cells2008226
Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis1997217
Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies1997215
Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus2001210
Rationale for interleukin-6 blockade in systemic lupus erythematosus2004209
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies2013205
A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group1998202
A review of health related quality of life in systemic lupus erythematosus2006192